WASHINGTON Die amerikanische Arzneimittelzulassungsbehörde FDA bestätigt zwei weitere PML-Erkrankungen in Europa und den USA. … weiter »
WASHINGTON Die amerikanische Arzneimittelzulassungsbehörde FDA bestätigt zwei weitere PML-Erkrankungen in Europa und den USA. … weiter »
Hi Huri,
thanx for your nice Fedback. Try this for further infos about rebound effcts: Immunologic and clinical status 14 months after cessation of natalizumab therapy [PMID: 18987352]
Best regards
Alex
I am sorry I do not speak German but I get the gist of your work. I hope you do not have a problem with my writing in English.
First, I would like to thank you and congratulate you on your work which provides scarce information on Tysabri and PML during the last 1,5 month (and even before).
Secondly, I would like to ask whether you have further information for current or former Tysabri users. I ask because after 18 months of treatment that stopped lesion activity in my brain, 2 months ago I decided to quit Tysabri because my spinal MRI shows a lot of MS damage and at the functional level I have not witnessed any stability and declined very much since starting Tysabri. Furthermore, your data shows that 4 out of 13 persons were diagnosed with PML between 12 and 17 months of treatment. Although I quit this medication I still am concerned that I might be at risk. Do you have any information of rebound effect or PML emergence after quitting?
Thank you for your attention,
Best regards.
Huri